Matrikynes® Clinical Study Published Clinical study shows that Xylyx Bio's Matrikynes® product significantly improves skin structure, function and appearance. Results from an independent clinical study confirmed the efficacy of Matrikynes® in reversing common signs of skin damage and aging, including reduction of lines and wrinkles. Xylyx Bio, a regenerative medicine company developing breakthrough technologies for organ and tissue repair, today announced findings from an independent clinical study confirming that its proprietary Matrikynes® ingredient is safe and highly effective for anti-aging and other topical skin applications. Study results are reported in a technical paper titled Clinical evaluation of Matrikynes®: a novel cosmetic ingredient comprised of matrikine peptides. Developed through biomedical research aimed at better understanding and supporting tissue repair and wound healing, Matrikynes® consists of a proprietary blend of peptides derived from natural extracellular matrix called matrikines. Matrikines have been shown to activate regenerative mechanisms that can direct tissue repair and reverse the effects of aging through their intrinsic bioactivity. The independent study evaluated the clinical safety and efficacy of Matrikynes® for topical skin applications in 56 female volunteers aged 35 to 65 representing different skin types and tones. Assessments were conducted using standard dermatological evaluations, clinical instrumentation and validated measurement techniques. Topical application of Matrikynes® demonstrated a robust clinical safety profile and numerous statistically significant improvements in the structure, function and appearance of damaged and aging skin.

Key Clinical Study Findings

• Safety testing showed no allergic sensitization or irritation reactions to Matrikynes®. • Topical application of Matrikynes® significantly improved skin barrier repair. • Topical application of Matrikynes® increased skin density and reduced the appearance of overall fine lines and deep wrinkles. Dr. John O'Neill, Chief Scientific Officer at Xylyx Bio, stated: "As a pioneer in regenerative medicine, Xylyx Bio developed Matrikynes® in response to increasing demand in topical skincare for evidence-based ingredients that can effectively address skin damage. This study validates that Matrikynes® is safe and delivers numerous functional and cosmetic benefits. Such significant reparative properties in a single ingredient pave the way for a new regenerative skincare paradigm." Source